Edwards Lifesciences has acquired Embrella Cardiovascular, the developer of the Embrella Embolic Deflector System that can be used during transcatheter heart valve procedures, for a purchase price of approximately $43 million in cash.
The single-use, disposable Embrella device is placed in the aorta through a sheath inserted in the right brachial or right radial artery. The company said its porous membrane allows blood flow to the brain while simultaneously deflecting embolic material. The Embrella Embolic Deflector System has been assessed in a limited clinical study in Europe and received CE mark in May 2010.
Additionally, the Irvine, Calif.-based Edwards said it is maintaining its earnings guidance for the year.